Navigation Links
Clinical trials for new Alzheimer's disease treatment to be awarded European Commission €6m funding
Date:5/25/2011

An international research consortium led by Trinity College Dublin that aims to develop a new Alzheimer's disease treatment has just been selected for grant funding of 6 million by the European Commission Seventh Framework Programme (FP7). The consortium NILVAD*, comprising 18 European universities, hospitals and pharmaceutical companies, will conduct European clinical trials of NILVADIPINE in the treatment of Alzheimer's disease (AD).

Trinity College Dublin researchers at the School of Medicine and St James's Hospital, Dublin, are coordinating this major clinical trial that will determine whether NILVADIPINE can improve memory and also slow the rate of progression of Alzheimer's disease. NILVADIPINE is an approved medication used for the treatment of high blood pressure and has been already shown to decrease the risk of developing dementia. There have been no new drug treatments developed for Alzheimer's disease since 2003.

Commenting on the significance of the clinical trials and research, Professor Brian Lawlor, Conolly Norman Professor of Old Age Psychiatry at Trinity College Dublin and Consultant Psychiatrist at St James's Hospital who is leading the research said: "Considering the devastating health and social cure impact that Alzheimer's disease has on Europeans, there is relatively little research funding made available to tackle this major killer. This research consortium, NILVAD represents a change in this trend in Europe and a step in the right direction. It not only offers hope for a new treatment but also strengthens research networks and collaborations in Europe and means that research developments in Alzheimer's disease can be accelerated for the benefit of all Europeans."

Alzheimer's disease is an ever-increasing public health concern among the ageing population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than 440,000 million each year (www.alz.org, 2010). It is estimated that by 2050, 1 in 85 of the population worldwide will have AD. There are few effective symptomatic treatments and as of the moment, no treatment that can delay or prevent Alzheimer's disease.

Treating high blood pressure with medications like NILVADIPINE have been shown to decrease the risk of developing dementia and Alzheimer's disease. In partnership with The Roskamp Institute in Florida, which developed the basic science evidence for the potential effectiveness of NILVADIPINE, Mercer's Institute for Successful Ageing at St James's Hospital, Dublin, conducted an earlier safety study also led by Professor Lawlor, on Alzheimer's disease patients that formed the basis for this new clinical trial. Now, in collaboration with key partners* and Alzheimer's disease experts, NILVAD will conduct these multi-centre European trials. The trials will determine if NILVADIPINE can improve memory and functioning but also slow the rate of progression of Alzheimer's disease. In preclinical studies NILVADIPINE lowers brain levels of amyloid which is thought to contribute to the development of Alzheimer's Disease. The study will be conducted over a period of 18 months involving 500 people.

Because NILVADIPINE is already available and licensed, this type of study can be carried out more quickly, to the potential benefit of future generations of people with Alzheimer's disease, their caregivers and society.


'/>"/>

Contact: Caoimhe Ni Lochlainn
communications@tcd.ie
353-189-62310
Trinity College Dublin
Source:Eurekalert

Related medicine news :

1. Dubai to host largest clinical bone meeting in the Middle East and Africa region
2. Top 5 list helps primary care doctors make wiser clinical decisions
3. Researchers examine procedure utilization trends in patients with clinically localized renal masses
4. TGen licenses first drug for patient use in clinical care
5. ENERCA clinical recommendations for sickle cell disease management and prevention in children
6. Tierney named 2011 Clinical and Translational Research Distinguished Investigator
7. New Pill for MS Shows Promise in Clinical Trial
8. First clinical trial of gene therapy for pain reported by U-M neurologists
9. Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network
10. New clinical practice guidelines developed for juvenile idiopathic arthritis
11. Bryan Roth honored for excellence in clinical pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: